Jyong Biotech's Exciting Achievement in Clinical Trials
Jyong Biotech Ltd., a prominent name in the biotechnology sector, has recently celebrated a significant milestone. The company has successfully completed patient enrollment for its Phase II clinical trial of MCS-8, an innovative drug candidate aimed at prostate cancer prevention. Over 700 high-risk participants have joined this clinical trial, marking a substantial step in the development of this groundbreaking medication.
Details of the Clinical Trial
The trial is structured as a randomized, placebo-controlled study and is being conducted at 20 hospitals across Taiwan, with the expertise of more than 130 urologists involved. Such a collaborative effort underscores Jyong Biotech's commitment to high-quality research and patient care.
Comments from Leadership
Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech, expressed her enthusiasm about reaching this pivotal milestone, especially during the ongoing challenges posed by the pandemic. "Enrolling over 700 participants reflects our team's dedication and professionalism," Kuo stated. Her comments indicate a profound appreciation for the team's efforts amid unprecedented times.
Future Expectations for MCS-8
While MCS-8 is still classified as an investigational drug and has not received regulatory approval yet, the company is anticipating a rigorous analysis of the trial data after the treatment period concludes. They are committed to transparency and will share results through appropriate channels, keeping all stakeholders informed.
About Jyong Biotech Ltd.
Founded in 2002, Jyong Biotech Ltd. has emerged as an innovative force in biotechnology, focusing on developing plant-derived drugs primarily for urinary system diseases. The company's headquarters in Taiwan serves as the hub for its diverse portfolio of biotechnology efforts. With a strong emphasis on research and development, it has cultivated capabilities in drug discovery, clinical trials, manufacturing, and commercial ventures.
Advancing Botanical Drug Candidates
Jyong Biotech's lineup includes various botanical drug candidates, with BOTRESO® being its flagship. This commitment to developing top-tier pharmaceutical options aims to meet global health needs and establish the company as a respected entity in the industry.
International Reach and Aspirations
Jyong Biotech targets international markets, focusing on the U.S., EU, and Asia. This strategy reflects a global vision to provide innovative and essential health solutions, making it a prominent player in the biotech landscape.
Frequently Asked Questions
What is the main purpose of Jyong Biotech's Phase II clinical trial?
The trial primarily aims to evaluate the effectiveness of MCS-8 in preventing prostate cancer in high-risk individuals.
How many participants were enrolled in the trial?
Over 700 participants have been successfully enrolled in the Phase II clinical trial of MCS-8.
Where is the clinical trial being conducted?
The trial is being conducted at 20 hospitals across Taiwan, involving over 130 urologists.
What does Jyong Biotech specialize in?
Jyong Biotech specializes in developing innovative plant-derived drugs focused primarily on treating urinary system diseases.
What are the next steps for MCS-8 after the trial?
After concluding the treatment period, the company will analyze the data and share the results in compliance with regulatory requirements.
